Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Dexamethasone and the UKALL 2011 trial

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 2071
Rating:

Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Dr Moppett speaks with ecancer at the 2017 ASH annual meeting about the UKALL 2011 trial, a randomised trial looking at a short induction dexamethasone schedule for children and young adults with acute lymphoblastic leukaemia, testing whether a 2 week induction dexamethasone schedule is less toxic than the standard 4 week schedule. 

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation